Ключевые слова:
профилактика, риск, нестобильная стенокардия, отеки.Библиографические ссылки
Ardans J., Economou A., Martinson J. et al. Oxidised low-density and high density lipoproteins regulate the production of matrix metalloproteinases-1 and -9 by activated monocytes // J. Leukoc. Biol.— 2002. — Vol. 71.— P. 1012—1018.
Cleutjiens J.P.M., Kandala J.C., Guarda E. et al. Regulation of collagen degradation in the rat myocardium after infarction // J. Mol. Cell Cardiol.— 1995.— Vol. 27.— P. 1281—1292.
Davies M.J. Coronary disease: the pathophysiology of acute coronary syndromes // Heart.— 2000.— Vol. 83.— P. 361—366.
Davies M.J. Reactive oxygen species, metalloproteinases, and plaque stability // Circulation.— 1998.— Vol. 97.— P. 2382—2383.
Ferroni P., Basili S., Martini F. et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation // J. Investig. Med.— 2003.— Vol. Sep 51, N 5.— P. 295—300.
Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodelling and atherogenesis: the good, the bad, and the ugly // Circ. Res.— 2002.— Vol. 90.— P. 251—262.
Galis Z.S., Sukhova G.K., Lark M.W. Increased expression of matrix metalloproteinase and matrix degrading activity in vulnerable regions of human atherosclerotic plaques // J. Clin. Invest.— 1994.— Vol. 94.— P. 2493—2503.
Gruber B.L., Sorbi D., French D.L. et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker // Clin. Immu - nol. Immunopathol.— 1996.— Vol. 78.— P. 161—171.
Hrabec E., Strek M., Nowak D., Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer // Respir. Med.— 2001.— Vol. 95.— P. 1—4.
Inokubo Y., Hanada H., Ishizaka H. et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome // Am. Heart J.— 2001.— Vol. 141, N 2.— P. 211 — 217.
Kai H., Ikeda H., Yasukawa H. et al. Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes // J. Am. Coll. Car- diol.— 1998.— Vol. 32.— P. 368—372.
Kalela A., Koivu T.A., Hoyhtya M. et al. Association of serum MMP-9 with autoantibodies against oxidized LDL // Atherosclerosis. — 2002.— Vol. 160, N 1.— P. 161—165.
Kalela A., Koivu T.A., Sisto T. et al. Serum matrix me- talloproteinase-9 con-centration in angiographically assessed coronary artery disease // Scand. J. Clin. Lab. Invest.— 2002.— Vol. 62.— P. 337—342.
Kelly E.A., Busse W.W., Jarjour N.N. Increased matrix metalloproteinase-9 in the airway after allergen challenge // Am. J. Respir. Crit. Care Med.— 2000.— Vol. 162.— P. 1157—1161.
Loftus I.M. Increased matrix MMP-9 activity in unstable carotid plaques: а potential role in acute plaque disruption // Stroke.— 2000.— Vol. 31.— P. 40—47.
Muzahir H. Tayebjee, Sunil Nadar, Andrew D. Blann. et al. Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Hypertension and Their Relationship to Cardiovascular Risk and Treatment // AJH.— 2004.— Vol. 17.— P. 764—769.
Nguyen M., Arkell J., Jackson C.J. Human endothelial gelatinases and angiogenesis // Int. J. Biochem. Cell Biol.— 2001.— Vol. 33.— P. 960—970.
Noji Y., Kajinami K., Kawashiri M. et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis // Clin. Chem. Lab. Med.— 2001.— Vol. 39.— P. 380—384.
Paramo J.A., Orbe J., Fernandez J. Fibrinolysis /proteolysis balance in stable angina pectoris in relation to angiographic findings // Thromb. Haemost.— 2001.— Vol. 86, N 2.— P. 636—639.
Veselka J., Prochazkova S., Duchonova R. et al. Relationship of Creactive protein to presence and severity of coronary atherosclerosis in patients with stable angina pectoris or a pathological exercise test // Coron. Artery Dis.— 2002.— Vol. 13 (3).— P. 151—154.